On Tuesday, Repligen got a positive adjustment to its Relative Strength (RS) Rating, from 69 to 74.
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an RS Rating of over 80 in the early stages of their moves. See if Repligen can continue to rebound and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Repligen is not currently offering a proper buying opportunity. See if the stock goes on to form a sound pattern that could kick off a new climb.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from -24% to 87%. Revenue rose from -3% to 10%.
Repligen earns the No. 9 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Medpace Holdings are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
